非霍奇金淋巴瘤 参考文献PPT
非霍奇金淋巴瘤（Non-Hodgkin Lymphoma, NHL）是一种起源于淋巴系统的恶性肿瘤，具有高度异质性，在病理学、生物学行为、治疗及预后等方面...
非霍奇金淋巴瘤（Non-Hodgkin Lymphoma, NHL）是一种起源于淋巴系统的恶性肿瘤，具有高度异质性，在病理学、生物学行为、治疗及预后等方面都存在着很大的差异。以下是非霍奇金淋巴瘤相关的参考文献综述，以满足您的需求。一、非霍奇金淋巴瘤的流行病学和病因学Smith AGHowlader N, Noone AM, et al. SEER Cancer Statistics Review, 1975-2016. Bethesda, MD: National Cancer Institute; 2019. [Available online: ]Siegel RLMiller KD, Jemal A. Cancer statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7-33Morton LMWang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276二、非霍奇金淋巴瘤的病理分类Swerdlow SHCampo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2017Alizadeh AAEisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511三、非霍奇金淋巴瘤的诊断和分期Cheson BDPfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology. 2007;25(5):579-586Moshkowitz MCzuczman MS. Imaging in the staging and restaging of lymphoma: current concepts and future directions. Journal of Nuclear Medicine. 2005;46(1):11S-22S四、非霍奇金淋巴瘤的治疗Coiffier BLepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine. 2002;346(4):235-242Habermann TMWeller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2006;24(19):3121-3127Specht L, Norton A, et al. Role of radiation therapy in the management of diffuse large B-cell lymphoma: an analysis of the National LymphoCare Study. Journal of Clinical Oncology. 2015;33(6):576-584Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861Klapper W, Reiter A, et al. The role of targeted therapy in the treatment of relapsed/refractory non-Hodgkin lymphoma. Blood Cancer Journal. 2018;8(10):107五、非霍奇金淋巴瘤的预后和生存Carbone PPKaplan LD, Musshoff K, et al. Report of the Committee on Hodgkin's DiseaseStaging Classification. Cancer Research. 1971;31(11):1860-1861Morton LMWang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276六、非霍奇金淋巴瘤的研究进展Armitage JOWeisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical
